Literature DB >> 11189200

SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.

B Costa1, M Colleoni.   

Abstract

AIM: To examine the acute actions of the CB1 cannabinoid receptor antagonist SR141716A [N-piperidino-5-(4-chlorophenyl)- 1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] on typical behavioral pattern of psychoactive cannabinoids in rats.
METHODS: At different time after injection the tail-flick response latency, the rectal temperature, the locomotor activity, and the immobility on a ring as well as the numbers of rears, self-grooming episodes (lasting 5 s), and fecal pellets were measured.
RESULTS: Acute administration of SR141716A (3 mg/kg i.p.) induced a significant increase in horizontal locomotor activity assayed by an activity meter, in stereotypic activity (such as rearing and self-grooming) and in defecation, and a decrease in nociceptive threshold recorded as tail-flick latency. This dose had no effect on ring immobility and did not change the body temperature.
CONCLUSION: These results demonstrate that this cannabinoid antagonist itself was inducing behavior opposite to that of CB1 receptor agonists.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11189200

Source DB:  PubMed          Journal:  Zhongguo Yao Li Xue Bao        ISSN: 0253-9756


  3 in total

Review 1.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Behavioral assessment of rimonabant under acute and chronic conditions.

Authors:  Robert Ettaro; Lucas Laudermilk; Stewart D Clark; Rangan Maitra
Journal:  Behav Brain Res       Date:  2020-05-15       Impact factor: 3.332

3.  SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors.

Authors:  Michaela Dvorakova; Agnieszka Kubik-Zahorodna; Alex Straiker; Radislav Sedlacek; Alena Hajkova; Ken Mackie; Jaroslav Blahos
Journal:  Br J Pharmacol       Date:  2021-02-27       Impact factor: 9.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.